Lineage Cell Therapeutics, Inc. (LCTX)
$
1.02
-0.04 (-3.92%)
Key metrics
Financial statements
Free cash flow per share
-0.0996
Market cap
232.9 Million
Price to sales ratio
24.3720
Debt to equity
0.0289
Current ratio
3.8188
Income quality
1.3696
Average inventory
0
ROE
-0.2242
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of innovative cell therapies aimed at treating degenerative diseases both domestically and internationally. The company's noteworthy advancements include OpRegen, a retinal pigment epithelium cell replacement therapy currently undergoing Phase I/IIa clinical trials for the treatment of dry age-related macular degeneration. Additionally, its OPC1 therapy focuses on oligodendrocyte progenitor cells and is also in Phase I/IIa multicenter clinical trials targeting acute spinal cord injuries. Lineage is further advancing VAC2, an allogeneic cancer immunotherapy utilizing antigen-presenting dendritic cells, which is in Phase I clinical trials for non-small cell lung cancer. The company also markets Renevia, a product aimed at enhancing facial aesthetics. In its commitment to innovation, Lineage engages in ongoing research and development of therapeutic products across areas such as retinal diseases, neurological disorders, and oncology. The company incurred an income tax expense of $27,000.00 indicating its tax obligations. Additionally, the operating income ratio is -2.26 which reflects the company's operational profitability margin, while the net income ratio is -1.96 showcasing the organization's overall profitability margin. This financial data pertains to the fiscal year 2024 and the weighted average number of shares outstanding is 200,193,000.00 highlighting the company's shareholder base. In the marketplace, Lineage Cell Therapeutics represents an affordable investment opportunity, with the stock priced at $1.02 making it suitable for budget-conscious investors. The stock exhibits a high average trading volume of 2,238,636.00 indicating strong liquidity, which is essential for active trading. With a market capitalization of $232,923,120.00 the company is classified as a small-cap player, establishing it as a key participant in the Biotechnology industry. Lineage significantly contributes to the broader market landscape, as it belongs to the Healthcare sector, driving innovation and fostering growth within its field.
Is Lineage Cell Therapeutics, Inc. (LCTX) a good investment?
Investing in Lineage Cell Therapeutics, Inc. (LCTX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Lineage Cell Therapeutics, Inc. (LCTX)'s stock forecast?
Analysts predict Lineage Cell Therapeutics, Inc. stock to fluctuate between $0.37 (low) and $1.15 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Lineage Cell Therapeutics, Inc.'s market capitalization?
As of 2025-07-10, Lineage Cell Therapeutics, Inc.'s market cap is $232,923,120, based on 228,356,000 outstanding shares.
How does Lineage Cell Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Lineage Cell Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. pays dividends. The current dividend yield is 5.56%, with a payout of $0.08 per share.
How can I buy Lineage Cell Therapeutics, Inc. (LCTX) stock?
To buy Lineage Cell Therapeutics, Inc. (LCTX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for LCTX. Place an order (Market, Limit, etc.).
What is the best time to invest in Lineage Cell Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Lineage Cell Therapeutics, Inc. stock ever split?
Lineage Cell Therapeutics, Inc.'s last stock split was 3:1 on 1997-10-31.
How did Lineage Cell Therapeutics, Inc. perform in the last earnings report?
Revenue: $9,499,000 | EPS: -$0.09 | Growth: -25%.
Where can I find Lineage Cell Therapeutics, Inc.'s investor relations reports?
Visit https://www.lineagecell.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Lineage Cell Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Lineage Cell Therapeutics, Inc. stock?
All-time high: $3.13 (2021-02-17) | All-time low: $0.37 (2025-04-09).
What are the key trends affecting Lineage Cell Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q1 2025 - Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Conference Call Participants William Wood - B. Riley Securities Jack Allen - Baird Michael Okunewitch - Maxim Group Albert Lowe - Craig Hallum Capital Group Operator Welcome to the Lineage Cell Therapeutics First Quarter 2025 Conference Call.
seekingalpha.com
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Conference Call Participants Jack Allen - Baird Joseph Pantginis - H.C. Wainwright Michael Okunewitch - Maxim Group Mayank Mamtani - Riley Securities Albert Lowe - Craig-Hallum Sean McCutcheon - Raymond James Operator Thank you for standing by.
247wallst.com
Since the beginning of the year, the number of notable insider purchases has been lower than usual.
zacks.com
Lineage Cell (LCTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
businesswire.com
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of the second tranche of its previously announced registered direct offering of an aggregate of up to $66 million. The Company had previously received $24 million in gross proceeds at the closing of the first tranche in November 2024. Today, the Company received an addit.
zacks.com
The heavy selling pressure might have exhausted for Lineage Cell (LCTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
businesswire.com
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the first closing of its previously announced registered direct offering for the purchase and sale of up to an aggregate of 39,473,688 of Lineage's common shares and accompanying warrants (the “common warrants”) to purchase an aggregate of up to 39,473,688 of Lineage's common shares.
zacks.com
Lineage Cell (LCTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
seekingalpha.com
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript
zacks.com
Lineage Cell (LCTX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.04 per share a year ago.
See all news
